ILMN — Illumina, Inc.

Summary of Illumina (ILMN) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $1.08 billion, exceeding guidance and reflecting roughly flat year-over-year growth.
• Revenue Growth (ex-China): Approximately 2% year-over-year.
• Non-GAAP Operating Margin: 24.5%, up 190 basis points year-over-year.
• Non-GAAP Diluted EPS: $1.34, representing an 18% increase year-over-year.
• Sequencing Consumables Revenue: $747 million, flat year-over-year but up 3% excluding China.
• Greater China Revenue: $52 million, with ongoing export restrictions impacting performance.

2. Strategic Updates and Business Highlights

• NovaSeq X Transition: Over 75% of high-throughput gigabases and 51% of revenue now from the NovaSeq X platform, with strong placements (over 55 instruments in Q3).
• Clinical Market Growth: Strong momentum driven by new assay approvals and increased demand for sequencing-intensive tests.
• Multiomics Expansion: Launched Illumina Protein Prep and expanded multiomics portfolio with new offerings, aiming to integrate with existing software solutions.
• BioInsight Launch: A new business unit to enhance genomic and multiomics data use in drug discovery and research.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Increased total revenue guidance to a range of $4.27 billion to $4.31 billion, reflecting a slight decline of 0.5% to 1.5% year-over-year.
• Clinical Growth Expectations: Anticipated strong growth in clinical revenue, with high single-digit growth projected for 2026.
• Research Market Outlook: Expected to remain muted in 2026, with gradual recovery anticipated as pricing headwinds ease.
• Earnings Growth: Confidence in achieving high single-digit revenue growth and 20% non-GAAP operating margins by 2027.

4. Bad News, Challenges, or Points of Concern

• China Operations: Ongoing export restrictions create uncertainty; while revenue exceeded guidance, a long-term resolution is still pending.
• Research Market Weakness: Continued funding uncertainty and pricing dynamics are impacting research consumables, leading to a high single-digit decline in revenue outside China.
• Competitive Pressures: Increased competition in the market, particularly from Roche, could impact growth, especially in the clinical segment.

5. Notable Q&A Insights

• China's Impact: Management is cautious about projecting future performance in China, emphasizing a quarter-by-quarter approach.
• Research Spending: There is a need for predictability in grant funding for researchers to increase spending; current conditions remain uncertain.
• Clinical Growth Drivers: New test approvals and the transition to NovaSeq X are expected to sustain clinical revenue growth.
• Margin Expansion: Continued focus on operational efficiency and cost structure improvements is expected to support further margin expansion in the future.
• Instrument Placements: Q4 is typically stronger for instrument placements, and management is optimistic about maintaining the 50-60 placements per quarter target.

Overall, Illumina demonstrated strong performance in Q3 2025, particularly in the clinical market, while navigating challenges in the research sector and ongoing uncertainties in China. The company remains focused on strategic initiatives to drive growth and innovation in the coming years.